FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to compositions, kits, method of preventing and treating cancer using tumour-associated recombinant MVA (modified vaccinia Ankara) viruses coding the antigens: PSA (prostate specific antigen) and PAP (prostatic acid phosphatase). The given recombinant MVA viruses are able to induce B- and T-cell responses. The recombinant MVA viruses may be also used in a combination with taxane.
EFFECT: recombinant modified viruses are effective in preventing and treating cancer.
23 cl, 27 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION THERAPY FOR TREATING CANCER WITH POXVIRUS EXPRESSING TUMOUR ANTIGEN AND ANTAGONIST AND/OR AGONIST OF IMMUNE CHECKPOINT INHIBITOR | 2014 |
|
RU2714142C2 |
| COMBINATION THERAPY FOR CANCER TREATMENT USING RECOMBINANT MVA AND ANTIBODIES INTRODUCED INTRAVENOUSLY | 2018 |
|
RU2795103C2 |
| PERSONALIZED VACCINE | 2018 |
|
RU2779987C2 |
| COMBINED THERAPY FOR TREATING CANCER USING A RECOMBINANT POXVIRUS EXPRESSING A TUMOR ANTIGEN AND AN ANTAGONIST OR AGONIST OF AN IMMUNE CONTROL POINT MOLECULE | 2015 |
|
RU2724433C2 |
| RECOMBINANT GENE STRUCTURE FOR INDUCING IMMUNE RESPONSE, RECOMBINANT POLYPEPTIDE AND VACCINE | 2005 |
|
RU2396348C2 |
| PROSTATE-ASSOCIATED ANTIGENS AND IMMUNOTHERAPEUTIC REGIMENS BASED ON VACCINES | 2013 |
|
RU2737765C2 |
| PROSTATE-ASSOCIATED ANTIGENS AND IMMUNOTHERAPY SCHEMES BASED ON VACCINES | 2013 |
|
RU2609651C2 |
| ANNEXIN A3 MONOCLONAL ANTIBODIES FOR DETECTION OF PROSTATE CARCINOMA | 2007 |
|
RU2467335C2 |
| METHODS OF TREATING CANCER USING ANTAGONISTS BINDING TO COMPONENTS OF THE SIGNAL PATH PD-1, AND TAXANES | 2014 |
|
RU2719487C2 |
| M2-DEFECTIVE POXVIRUS | 2019 |
|
RU2819245C2 |
